UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 44

Sortiert nach

Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer

Nature communications, 2018-11, Vol.9 (1), p.4664-5, Article 4664

2018

Link zum Volltext

Verfügbarkeit prüfen

Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non-Small Cell Lung Cancer

Clinical cancer research, 2017-08, Vol.23 (15), p.4251-4258

2017

Link zum Volltext

Verfügbarkeit prüfen

Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer

European journal of cancer (1990), 2022-08, Vol.171, p.114-123

2022

Link zum Volltext

Verfügbarkeit prüfen

Repeatability of quantitative 18F-FLT uptake measurements in solid tumors: an individual patient data multi-center meta-analysis

European journal of nuclear medicine and molecular imaging, 2018-06, Vol.45 (6), p.951-961

2018

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

The New England journal of medicine, 2016-11, Vol.375 (19), p.1823-1833

2016

Link zum Volltext

Verfügbarkeit prüfen

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

The New England journal of medicine, 2017-02, Vol.376 (7), p.629-640

2017

Link zum Volltext

Verfügbarkeit prüfen

Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer

The New England journal of medicine, 2024-01, Vol.390 (2), p.118-131

2024

Link zum Volltext

Verfügbarkeit prüfen

Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib

OncoTargets and therapy, 2017-01, Vol.10, p.4535-4541

2017

Link zum Volltext

Verfügbarkeit prüfen

Cachexia in chronic obstructive pulmonary disease: new insights and therapeutic perspective

Journal of cachexia, sarcopenia and muscle, 2016-03, Vol.7 (1), p.5-22

2016

Link zum Volltext

Verfügbarkeit prüfen

Physical exercise at the crossroad between muscle wasting and the immune system: implications for lung cancer cachexia

Journal of cachexia, sarcopenia and muscle, 2022-02, Vol.13 (1), p.55-67

2022

Link zum Volltext

Verfügbarkeit prüfen

A novel orthotopic mouse model replicates human lung cancer cachexia

Journal of cachexia, sarcopenia and muscle, 2023-06, Vol.14 (3), p.1410-1423

2023

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab for all PD-L1-positive NSCLC

The Lancet (British edition), 2019-05, Vol.393 (10183), p.1776-1778

2019

Link zum Volltext

Verfügbarkeit prüfen

Exposure–Response Analysis of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer Patients in a Real-Life Setting

Pharmaceutical research, 2022-10, Vol.39 (10), p.2507-2514

2022

Link zum Volltext

Verfügbarkeit prüfen

Identification of microRNAs in skeletal muscle associated with lung cancer cachexia

Journal of cachexia, sarcopenia and muscle, 2020-04, Vol.11 (2), p.452-463

2020

Link zum Volltext

Verfügbarkeit prüfen

PD-L1 IHC in NSCLC with a global and methodological perspective

Lung cancer (Amsterdam, Netherlands), 2017-11, Vol.113, p.102-105

2017

Link zum Volltext

Verfügbarkeit prüfen

PD-L1 PET/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non-Small Cell Lung Cancer

Journal of Nuclear Medicine, 2022-05, Vol.63 (5), p.686-693

2022

Link zum Volltext

Verfügbarkeit prüfen

Clinical Relevance of High Plasma Trough Levels of the Kinase Inhibitors Crizotinib, Alectinib, Osimertinib, Dabrafenib, and Trametinib in NSCLC Patients

Therapeutic drug monitoring, 2024-02, Vol.46 (1), p.73

2024

Link zum Volltext

Verfügbarkeit prüfen

Deep Learning Based Automated Orthotopic Lung Tumor Segmentation in Whole-Body Mouse CT-Scans

Cancers, 2021-09, Vol.13 (18), p.4585

2021

Link zum Volltext

Verfügbarkeit prüfen

Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications

Therapeutic Advances in Medical Oncology, 2017-01, Vol.9 (1), p.46-58

2017

Link zum Volltext

Verfügbarkeit prüfen

A phase 2 trial combining afatinib with cetuximab in patients with EGFR exon 20 insertion–positive non–small cell lung cancer

Cancer, 2024-03, Vol.130 (5), p.683-691

2024

Link zum Volltext

Verfügbarkeit prüfen

Association of tumour and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with DCB and OS to nivolumab treatment in NSCLC patients pre-treated with chemotherapy

British journal of cancer, 2020-08, Vol.123 (3), p.392-402

2020

Link zum Volltext

Verfügbarkeit prüfen

Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment

British journal of cancer, 2018-08, Vol.119 (5), p.558-564

2018

Link zum Volltext

Verfügbarkeit prüfen

Novel strategies in newborn screening for cystic fibrosis: a prospective controlled study

Thorax, 2012-04, Vol.67 (4), p.289-295

2012

Link zum Volltext

Verfügbarkeit prüfen

Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients

Clinical cancer research, 2018-03, Vol.24 (6), p.1337-1343

2018

Link zum Volltext

Verfügbarkeit prüfen

Sotorasib in KRAS G12C mutated lung cancer - Authors' reply

The Lancet (British edition), 2024-01, Vol.403 (10422), p.145

2024

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 44

Suche als RSS-Feed

Aktive Filter

ThemaCardiovascular System

ThemaLung Cancer

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(44)
Mit Volltextzugriff
(43)

Publikationsform

Artikel
(44)

Sprache

Englisch
(44)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

Science & Technology
(30)
Life Sciences & Biomedicine
(29)
Patients
(24)
Non-Small Cell Lung Carcinoma
(23)
Tumors
(21)
Oncology
(20)
Humans
(18)
Mutation
(14)
Small Cell Lung Carcinoma
(14)
Tomography
(13)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(12)
Lung Neoplasms - Drug Therapy
(12)
Targeted Cancer Therapy
(12)
Cancer Therapies
(11)
General & Internal Medicine
(11)
Medicine, General & Internal
(11)
Positron Emission
(11)
Cancer
(10)
Medical Imaging
(10)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer

Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non-Small Cell Lung Cancer

Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer

Repeatability of quantitative 18F-FLT uptake measurements in solid tumors: an individual patient data multi-center meta-analysis

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer

Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib

Cachexia in chronic obstructive pulmonary disease: new insights and therapeutic perspective

Physical exercise at the crossroad between muscle wasting and the immune system: implications for lung cancer cachexia

A novel orthotopic mouse model replicates human lung cancer cachexia

Pembrolizumab for all PD-L1-positive NSCLC

Exposure–Response Analysis of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer Patients in a Real-Life Setting

Identification of microRNAs in skeletal muscle associated with lung cancer cachexia

PD-L1 IHC in NSCLC with a global and methodological perspective

PD-L1 PET/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non-Small Cell Lung Cancer

Clinical Relevance of High Plasma Trough Levels of the Kinase Inhibitors Crizotinib, Alectinib, Osimertinib, Dabrafenib, and Trametinib in NSCLC Patients

Deep Learning Based Automated Orthotopic Lung Tumor Segmentation in Whole-Body Mouse CT-Scans

Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications

A phase 2 trial combining afatinib with cetuximab in patients with EGFR exon 20 insertion–positive non–small cell lung cancer

Association of tumour and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with DCB and OS to nivolumab treatment in NSCLC patients pre-treated with chemotherapy

Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment

Novel strategies in newborn screening for cystic fibrosis: a prospective controlled study

Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients

Sotorasib in KRAS G12C mutated lung cancer - Authors' reply

Aktive Filter

Suchergebnisse filtern